IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.

A session dives into the trends surrounding specialty drugs and therapies, along with providing an overview of the drug ...

Blake Powers, CEO, Medigi, discusses how face-to-face collaboration and streamlined commercialization strategies are helping ...

Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.

In a press release, Merck KGaA CEO and chair of the executive board Belen Garijo said, “The agreed acquisition of SpringWorks is a major step in our active portfolio strategy to position Merck KGaA, ...

Led by Brett Casper, a senior principal at Blue Fin Group, his agenda revolved around outlining the evolving orthodoxies for commercialization of ORD, CGT, and precision medicine; commercialization ...

Tiara Green, president, Accessia Health, highlights key themes from the upcoming discussion on how health equity, literacy, and social determinants are reshaping patient care—especially for those with ...

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on ...

The Regeneron SVP details the company’s approach to reaching oncology patients across the planet.

CMS’ draft guidance on real-world data study protocols marks a significant move toward transparency and rigor in Medicare ...

Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced ...

Ferring Pharmaceuticals announced strong performance results for 2024, with one part of the announcement standing out as ...